NASDAQ$STOK
Stoke Therapeutics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Stoke Therapeutics reported financial results for the third quarter of 2024 and provided business updates.
Stoke Therapeutics reported revenue of $4.9 million and a net loss of $26.4 million for the third quarter of 2024. The company had $269.2 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
- Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end.
- Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zorevunersen continue to progress; Company to provide an update by year-end.
- FDA has removed the Partial Clinical Hold on zorevunersen.
- As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Stoke Therapeutics · Revenue · Quarterly
$4.89M
Revenue by segment
Stoke Therapeutics · $3.27M total across 1 segment · Q4 2022
- Acadia Pharm.$3.27M—100.0%
Forward guidance
The Company plans to provide an update on Phase 3 registrational plans for zorevunersen by year-end.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+4.2%
Avg return
Earnings day
+4.9%
Avg return
5 days after
+3.1%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+63.3%
Q4 2023
Best reaction
-20.0%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.5% | -2.6% | -9.8% | |
| Q4 2025 | -2.8% | -1.3% | +4.1% | |
| Q3 2025 | -10.1% | -11.7% | +21.8% | |
| Q1 2025 | +1.2% | -1.6% | +19.7% | |
| Q4 2024 | -1.4% | -9.4% | -14.6% | |
| Q3 2024 | +1.1% | +6.0% | -4.0% | |
| Q2 2024 | -0.6% | +1.5% | +3.3% | |
| Q1 2024 | -0.7% | -4.5% | +36.5% | |
| Q4 2023 | +63.3% | +114.3% | +85.1% | |
| Q3 2023 | +7.0% | -1.2% | +6.7% | |
| Q2 2023 | -9.3% | -11.1% | -13.4% | |
| Q1 2023 | +25.9% | +28.1% | +28.2% | |
| Q4 2022 | +4.5% | -1.0% | -10.1% | |
| Q3 2022 | -20.0% | -35.9% | -32.9% | |
| Q2 2022 | +31.7% | +28.6% | -10.8% | |
| Q1 2022 | +2.0% | +17.3% | +0.6% | |
| Q4 2021 | -1.6% | -2.1% | +9.8% | |
| Q3 2021 | +3.0% | +9.4% | -20.2% | |
| Q2 2021 | -1.4% | -2.4% | -1.6% | |
| Q1 2021 | +11.3% | +9.9% | +26.6% | |
| Q4 2020 | +6.8% | +1.5% | -30.2% | |
| Q3 2020 | -0.5% | -7.8% | +14.6% | |
| Q2 2020 | +4.7% | +8.5% | +18.6% | |
| Q1 2020 | +15.3% | +18.9% | -6.0% | |
| Q4 2019 | -3.9% | -2.3% | -6.5% | |
| Q3 2019 | -11.1% | -21.7% | -20.0% | |
| Q2 2019 | +0.0% | +5.3% | -11.4% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro